The National Health Service (NHS) in England and Wales is now offering the first drug approved to delay the onset of type 1 diabetes. The immunotherapy, known as teplizumab, can provide individuals with up to three additional years before they develop symptoms requiring lifelong insulin therapy.
The NHS medicines body has described the decision as "genuinely exciting," anticipating that hundreds of children and young people could benefit annually. Type 1 diabetes, an autoimmune condition where the body's immune system attacks insulin-producing cells in the pancreas, can manifest at any age, though it is most commonly diagnosed in the early teenage years.
Patient advocacy groups have hailed the drug's availability as "momentous" following decades of research and development. "If it were your child or someone you love, you would want to do everything possible to give them more years without the daily burden of managing this relentless condition," stated Karen Addington, chief executive of the charity Breakthrough T1D, emphasizing that the treatment now makes this possible.
Unlike type 2 diabetes, which is often associated with weight, type 1 diabetes is characterized by the body's inability to produce sufficient insulin. Individuals diagnosed with type 1 diabetes must regularly monitor their blood glucose levels and administer insulin through injections or a pump to manage the condition.